Reports

•In 2017, Ohio guidelines were passed to reduce acute pain opioid prescriptions •We compared pre/post-guidelines opioid scripts for hip and knee arthroplasty

Researchers found that white males ages 30 to 39 were most at risk of fatal overdoses in Ohio. The study also identified 12 clusters in the state where overdose rates were highest.

AMES, Iowa - The United States is suffering from several different simultaneous opioid epidemics, rather than just a single crisis, according to an academic study of deaths caused by drug overdoses.

Opioid misuse and deaths are increasing in the United States. In 2017, Ohio had the second highest overdose rates in the US, with the city of Cincinnati experiencing a 50% rise in opioid overdoses since 2015.

Federal money to fight the opioid crisis nearly doubled in the last two years, according to a national think tank’s new report analyzing that funding.

To address the growing misuse and diversion of prescription drugs, the Ohio General Assembly adopted legislation in 2004 authorizing the State of Ohio Board of Pharmacy to create a Prescription Monitoring Program (PMP), known as the Ohio Automated Rx Reporting System (OARRS). Established in 2006, OARRS collects information on all outpatient prescriptions for controlled substances and two non-controlled substances (gabapentin and naltrexone) dispensed by Ohiolicensed pharmacies and personally furnished by Ohio prescribers. This data is reported every 24 hours and is maintained in a secure database. Drug wholesalers and manufacturers are also required to submit information monthly on all controlled substances and gabapentin sold to an Ohio licensed pharmacy or prescriber.

The following items are recommendations from the Governor's Cabinet Opiate Action Team of information that should be included to meet the health instruction requirement focused on “Prescription opioid abuse prevention, with an emphasis on the prescription drug epidemic and the connection between prescription opioid abuse and addiction to other drugs, such as heroin.”

In 2017, the United States recorded 70,237 drug overdose deaths; among these, 47,600 (67.8%) involved an opioid, and 28,466 (40.5%) involved a synthetic opioid other than methadone (e.g., fentanyl and tramadol) (1). During 2013–2017, sustained growth in the availability of illicitly manufactured fentanyl (IMF) drove large increases in overdose deaths involving a synthetic opioid other than methadone (1). Specifically, the number of drug products obtained by law enforcement that were submitted for laboratory testing and tested positive for fentanyl (fentanyl submissions) increased rapidly, especially in the Midwest and Northeast U.S. Census regions.